Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
SELP Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SELP Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SELP sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SELL Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SELL Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SELL sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SDC4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SDC4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SDC4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SDC3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SDC3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SDC3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SDC2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SDC2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SDC2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SDC1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SDC1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SDC1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SCN11A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SCN11A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SCN11A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SCN10A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SCN10A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SCN10A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SCN9A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SCN9A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SCN9A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SCN8A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SCN8A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SCN8A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SCN5A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SCN5A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SCN5A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
SCN4A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
SCN4A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of SCN4A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →